‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Dealmaking in 2026 is off to a strong start, driven by looming patent cliffs, buoyant public markets, and Big Pharma’s push to strengthen pipelines. The article points to a supportive backdrop for healthcare M&A, but it does not cite a specific transaction or quantitative market move. Overall tone is constructive for the sector, with limited immediate market impact absent deal details.

Analysis

Dealmaking in 2026 is off to a strong start, driven by looming patent cliffs, buoyant public markets, and Big Pharma’s push to strengthen pipelines. The article points to a supportive backdrop for healthcare M&A, but it does not cite a specific transaction or quantitative market move. Overall tone is constructive for the sector, with limited immediate market impact absent deal details.